Real-world safety and efficacy of omalizumab in patients with severe allergic asthma: A long-term post-marketing study in Japan

Article ID	Journal	Published Year	Pages	File Type
8819839	Respiratory Medicine	2018	8 Pages	PDF

Abstract

This post-marketing study confirmed the clinically meaningful benefits of omalizumab in a majority of patients from Japan, and showed safety and efficacy in a real-life clinical setting to be consistent with previous reports.

Keywords

PMS PMDA ADRs SABA SAEs LTRA ICS IgE OCs Aes Severe asthma leukotriene antagonist Long-acting β2-agonist Short-acting β2-agonist Effectiveness Health care resource utilization standard deviation Omalizumab Immunoglobulin E Exacerbations Adverse drug events GETE LABA Global Initiative for Asthma Adverse drug reaction Adverse events serious adverse events Post marketing surveillance international units quartile oral corticosteroid Inhaled corticosteroid GINA

Related Topics

Health Sciences Medicine and Dentistry Pulmonary and Respiratory Medicine

Preview

Real-world safety and efficacy of omalizumab in patients with severe allergic asthma: A long-term post-marketing study in Japan

Authors

Mitsuru Adachi, Masanari Kozawa, Hajime Yoshisue, Ki Lee Milligan, Makoto Nagasaki, Takayoshi Sasajima, Terumasa Miyamoto, Ken Ohta,